Study summary · research use only
PT-141 Palatin
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This brief note reports that Palatin, under license from Competitive Technology, was developing the peptide PT-141, described as a synthetically modified analog of PT-14, as a nasal spray for potential treatment of erectile dysfunction and female sexual dysfunction. It states that by September 2003 Palatin had completed a phase IIb trial in men with erectile dysfunction and, as of February 2004, planned to begin phase III trials in early 2005. No outcome data are reported.
Abstract
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.